Gilead forks over $40M to settle thousands of claims in web of litigation over alleged delay of safer HIV meds

As Gilead Sciences awaits the progression of California state litigation over its alleged delay of safer HIV drugs, the company is biding its time with a proposed $40 million settlement to quell the claims of more than 2,000 plaintiffs.

The concurrent cases revolve around Gilead’s older tenofovir disoproxil fumarate (TDF) based medicine, or Viread, Truvada and others, and its newer product made with tenofovir alafenamide fumarate (TAF), Vemlidy.